Cited by 294Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.

Meyers, P A, Gorlick, R, Heller, G, Casper, E, Lane, J, Huvos, A G, Healey, J H·1998·Journal of Clinical Oncology

DOI 10.1200/jco.1998.16.7.2452

Open this paper in CoChat — free account

Abstract

PURPOSE: It has been observed previously in osteosarcoma (OS) that the degree of necrosis of the resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent event-free survival (EFS). The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS. PATIENTS AND METHODS: Seventy-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T12 protocol between 1986 and 1993. Patients were randomized between therapy based on the T10 protocol and therapy with more intensive preoperative chemotherapy. The more intensive preoperative regimen consisted of two courses of cisplatin (CDDP) and doxorubicin (DOX) in addition to the usual preoperative regimen of high-dose methotrexate (HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD). RESULTS: The regimen with more intensive preoperative chemotherapy achieved a modest increase in the proportion of patients with a good histologic response (44% with a grade III or IV histologic response v 37% in the control arm, 33% with grade IV histologic response v 13% in the control arm). EFS continued to correlate with histologic response. The actuarial 5-year EFS in patients with localized disease was 78% for the regimen with more intensive preoperative chemotherapy and 73% for the control arm. CONCLUSION: Despite modest increases in the proportion of patients with good histologic response with intensified preoperative chemotherapy, no improvement in EFS was observed.

Integrity signals

Registry

Crossref · 10.1200/jco.1998.16.7.2452

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B. M., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6 · Cited by 1,082
Self-citation
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675
Self-citation
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584
Self-citation
Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
Eilber, F. R., Giuliano, A. E., Eckardt, J. J., Patterson, K., Moseley, S. H., & Goodnight, J. E. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.21 · Cited by 524
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.
Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M., Makley, J. T., Yunis, E. J., Huvos, A. G., Betcher, D. L., Baum, E. S., Kisker, C. T., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.76 · Cited by 458
Self-citation
Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 457
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Applewhite, A., Sun, M., & LaQuaglia, M. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 389
Self-citation

Flagged first, then by citations

Show all 18 references

1 of the 18 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–294 of 294

The Cause and Clinical Significance of Central Tumor Photopenia on Thallium Scintigraphy of Pediatric Osteosarcoma of the Extremity
McCarville, M. B., Barton, E. H., Cameron, J. R., Xiong, X., Daw, N. C., Kaste, S. C., Wu, S., Glass, J. O., & Reddick, W. E. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.0292 · Cited by 11
Analysis of imaging characteristics of primary malignant bone tumors in children
Sun, Y., Liu, X., Pan, S., Deng, C., Li, X., & Guo, Q. (2017) · Oncology Letters · doi:10.3892/ol.2017.6939 · Cited by 11
The impact of surgical resection margins on outcomes for adults with head and neck osteosarcomas: A Canadian sarcoma research and Clinical Collaboration (CanSaRCC) study
Tzelnick, S., Soroka, H. P., Tasnim, N., Gilbert, R. W., Irish, J. C., Goldstein, D. P., Brown, D. H., Gullane, P. J., Chepeha, D. B., Yao, C. M. K. L., et al. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106495 · Cited by 10
Long‐term survival after intralesional resection and multi‐modal therapy of thoracic spine osteosarcoma
Gore, L., Greffe, B. S., Rothenberg, S. S., Erickson, M. A., Schreiber, D. P., & Handler, M. H. (2003) · Medical and Pediatric Oncology · doi:10.1002/mpo.10255 · Cited by 10
PEDIATRIC OSTEOSARCOMA: A 35-Year Experience in Slovenia
Kuhelj, D., & Jereb, B. (2005) · Pediatric Hematology and Oncology · doi:10.1080/08880010590935257 · Cited by 10
Assessment of tumor necrotic fraction by dynamic contrast‐enhanced MRI: a preclinical study of human tumor xenografts with histopathologic correlation
Koh, T. S., Thng, C. H., Hartono, S., Dominguez, L. T. M., Lim, T. K. H., Huynh, H. T., Martarello, L., & Ng, Q. S. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3090 · Cited by 10
Inferior Vena Cava Thrombus Removal Using Hypothermic Circulatory Arrest in Two Patients with Osteosarcoma
Garcia, N. D., Morasch, M. D., Sam, A. D., Satcher, R. L., Blum, M. G., & Fullerton, D. A. (2003) · Annals of Vascular Surgery · doi:10.1007/s10016-003-0077-z · Cited by 10
Adenovirus-delivered PDCD5 counteracts adriamycin resistance of osteosarcoma cells through enhancing apoptosis and inhibiting Pgp.
Zhao, H., Peng, C., Ruan, G., Zhou, J., Li, Y., & Hai, Y. (2014) · PubMed Central · Cited by 9
Chemotherapy Regimens for Patients with Newly Diagnosed Malignant Bone Tumors
Roberts, R. D., Wedekind, M. F., & Setty, B. A. (2015) · Pediatric oncology · doi:10.1007/978-3-319-18099-1_6 · Cited by 9
Controversies and Challenges in the Management of Osteosarcoma—an Indian Perspective
Mittal, A., Pushpam, D., Ganguly, S., Kumar, V. S., Khan, S. A., & Bakhshi, S. (2022) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01486-3 · Cited by 11
Osteogenic Sarcoma in Children and Young Adults
Aung, L., Tin, A. S., Quah, T. C., & Pho, R. W. H. (2014) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v43n6p305 · Cited by 9
A European treatment protocol for bone sarcoma in patients older than 40 years
Ferrari, S., Smeland, S., Bielack, S., Comandone, A., Dileo, P., Picci, P., Hall, K. S., Eriksson, M., Honegger, H., & Reichardt, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.10516 · Cited by 9
Role of microRNA-503 in the suppression of osteosarcoma cell proliferation and migration via modulation of fibroblast growth factor 2
Wu, B., & Bi, W. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4399 · Cited by 8
Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma
Lancia, C., Anninga, J., Spitoni, C., Sydes, M. R., Whelan, J. S., Hogendoorn, P. C. W., Gelderblom, H. A. J., & Fiocco, M. F. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022980 · Cited by 8
Intra-Arterial Cisplatin in Osteosarcoma: Same Question, Different Answer
Rao, B. N., & Galindo, C. R. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.04.903 · Cited by 8
Alkaline phosphatase, lactic dehidrogenase, inflammatory variables and apparent diffusion coefficients from MRI for prediction of chemotherapy response in osteosarcoma. A cross sectional study
Kamal, A. F., Abubakar, I., & Salamah, T. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102228 · Cited by 8
Nomogram for predicting disease-specific survival in osteosarcoma
Yang, X., Yang, Y., Weng, X., & Zhang, M. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001837 · Cited by 7
Secondary Malignant Neoplasms after Osteosarcoma: Early Onset and Cumulative Alkylating Agent Dose Dependency
Kim, S. H., Shin, K.-H., Seok, S. O., Cho, Y. J., Noh, J. K., Suh, J., & Yang, W. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4070-2 · Cited by 7
Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma
Kim, S. H., Shin, K.-H., Moon, S., Kong, Y., Suh, J., & Yang, W. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24571 · Cited by 7
Long‐term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate
Stine, K. C., Saylors, R. L., Saccente, S. L., & Becton, D. L. (2003) · Medical and Pediatric Oncology · doi:10.1002/mpo.10311 · Cited by 7
Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
Sohn, J., Rha, S. Y., Jeung, H., Shin, H. J., Goo, Y. S., Chung, H. C., Yang, W. I., Hahn, S. B., Shin, K. H., Min, J. S., et al. (2001) · Cancer Research and Treatment · doi:10.4143/crt.2001.33.6.520 · Cited by 7
Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
Ganguly, S., Sasi, A., Khan, S. A., Kumar, V. S., Kapoor, L., Sharma, M. C., Mridha, A. R., Barwad, A. W., Thulkar, S. P., Pushpam, D., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1148480 · Cited by 6
Metastatic Cancer to Lung
Donington, J. S. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_93 · Cited by 6
Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population
Yonemori, K., Yamaguchi, U., Kaneko, M., Uno, H., Takeuchi, M., Ando, M., Fujiwara, Y., Hosono, A., Makimoto, A., Hasegawa, T., et al. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0295-9 · Cited by 6
Association between laboratory markers and oncological outcomes in patients with osteosarcoma – A review of osteosarcoma treatment in Indonesia
Kamal, A. F., & Prasetyo, R. A. (2018) · Formosan Journal of Surgery · doi:10.4103/fjs.fjs_140_17 · Cited by 6
Pediatric Solid Tumors
Dome, J. S., Galindo, C. R., Spunt, S. L., & Santana, V. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50103-2 · Cited by 7
Osteosarcoma
Janeway, K. A., Gorlick, R. G., & Bernstein, M. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00022-4 · Cited by 6
Self-citation
Cancer Stem Cells of Sarcoma
Fujiwara, T., Kawai, A., & Yoshida, A. (2013) · CRC Press eBooks · doi:10.1201/b15734-5 · Cited by 5
Pre-chemotherapy preservation of fertility in male patients with high-grade malignant bone and soft tissue tumors
Hoshi, M., Oebisu, N., Takada, J., Iwai, T., Rie, T., & Nakamura, H. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.367 · Cited by 5
Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu, T., Wang, J., Chen, Y., Tang, Y., & Huang, C.-H. (2009) · PubMed · Cited by 5
Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
Tanaka, K., Kawano, M., Iwasaki, T., Matsuda, S., Itonaga, I., & Tsumura, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-65591-z · Cited by 5
Osteosarcoma
Meyers, P. A. (2005) · Springer eBooks · doi:10.1007/3-540-29447-3_10 · Cited by 5
Self-citation
Development of Acute Myeloid Leukemia After Chemotherapy for Osteosarcoma
Kawai, A., Sugihara, S., Naito, N., Ozaki, T., Isu, K., Hatae, Y., & Inoue, H. (2001) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200110000-00027 · Cited by 5
Imaging Techniques: Magnetic Resonance Imaging
Hwang, S., & Panicek, D. M. (2009) · Medical radiology · doi:10.1007/978-3-540-77984-1_3 · Cited by 4
Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas
Wang, B., Yao, H., Xie, X., Yin, J., Zou, C., Huang, G., & Shen, J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3592-x · Cited by 4
Primary mammary osteogenic sarcoma.
Khaldi, L., Athanasiou, E., & Hadjitheofilou, C. T. (2007) · PubMed · doi:10.14670/hh-22.373 · Cited by 4
In vitro Effects of Canine Wharton’s Jelly Mesenchymal Stromal Cells and Micellar Nanoparticles on Canine Osteosarcoma D17 Cell Viability
Higginbotham, M. L. (2012) · Journal of Veterinary Science & Technology · doi:10.4172/2157-7579.1000118 · Cited by 4
Estimation of Potential Excess Cancer Incidence in Pediatric 201Tl Imaging
Kaste, S. C., Waszilycsak, G. L., McCarville, M. B., & Daw, N. C. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.2918 · Cited by 4
Osteosarkome
Zoubek, A., Windhager, R. H., & Bielack, S. (2005) · Springer eBooks · doi:10.1007/3-540-29036-2_71 · Cited by 4
Outcome after relapse in childhood and adolescent osteosarcoma: single institution experience in Korea
Lee, Y. J., Lee, H.-J., Kim, D.-H., Lim, J.-S., Lee, J.-H., Park, K.-D., Lee, S., & Jeon, D. (2008) · Korean Journal of Pediatrics · doi:10.3345/kjp.2008.51.1.78 · Cited by 3
CORR Insights®: Survival, Recurrence, and Function After Epiphyseal Preservation and Allograft Reconstruction in Osteosarcoma of the Knee
Fabbri, N. (2015) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-014-4121-9 · Cited by 3
Cancer Stem Cells of Sarcoma
Fujiwara, T., Kawai, A., Yoshida, A., Ozaki, T., & Ochiya, T. (2013) · CRC Press eBooks · doi:10.1201/b15734-3 · Cited by 3
Surgical Treatment of Tumors and Tumor-Like Lesions of Bone
Walczak, B. E., Rose, P. S., Post, J. M., & Sim, F. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-28315-5_8 · Cited by 3
Target concentration achievement for efficacy and safety of patients with osteosarcoma treated with high‑dose methotrexate based on individual pharmacokinetics: A retrospective study
Nagamine, A., Araki, T., Yashima, H., Kamimura, A., Shiraishi, T., Yanagawa, T., Obayashi, K., & Yamamoto, K. (2022) · Oncology Letters · doi:10.3892/ol.2022.13656 · Cited by 3
Tumor-associated-antigens or osteosarcoma cell line lysates: Two efficient methods for in vitro generation of CTLs with special regard to MHC-I restriction
Muraro, M., Mereuta, O. M., Saglio, F., Carraro, F., Cravero, C., & Fagioli, F. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.09.007 · Cited by 3
Bone sarcomas
Hartmann, J. T., & Kopp, H. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.04.008 · Cited by 3
Malignant Tumors of Bone
Heck, R. K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-07243-4.00027-x · Cited by 3
Cell Cycle Checkpoints p16 and p21—Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma
Nasri, E., Torrence, D. E., Vasilopoulos, T., Knapik, J. A., Lagmay, J., Reith, J. D., & Gibbs, C. P. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000714 · Cited by 2
[Diagnosis and treatment of primary osteosarcoma in 2009].
Piperno-Neumann, S. (2010) · PubMed · doi:10.1684/bdc.2010.1123 · Cited by 2
Treating pediatric osteosarcoma: recent clinical trial evidence
Abrams, A. K., Avedian, R. S., & Marina, N. M. (2013) · Clinical Investigation · doi:10.4155/cli.13.89 · Cited by 2
Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma: a meta-analysis.
Wang, W., Zc, W., Shen, H., Xie, J., & Lu, H. (2014) · PubMed · Cited by 2
Managing axial bone sarcomas in childhood
Meazza, C., Luksch, R., & Luzzati, A. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1891886 · Cited by 2
What has changed in the last 25 years in osteosarcoma treatment? A single center experience
Ataseven, E., Burak, Z., Sabah, D., Doğanavşargıl, B., Argın, M., Keçeci, B., Tamsel, İ., Kaya, H., Göktepe, Ş. Ö., & Kantar, M. (2023) · The Turkish Journal of Pediatrics · doi:10.24953/turkjped.2022.463 · Cited by 4
Chemotherapy for Adult Tumors
Wilson, M. W., & Galindo, C. R. (2005) · Springer eBooks · doi:10.1007/0-387-27086-8_35 · Cited by 2
Chemotherapy for non-metastatic high-grade osteosarcoma of extremity - Is neoadjuvant better than adjuvant?
Ngan, R. (2003) · The HKU Scholars Hub (University of Hong Kong) · Cited by 1
Treatment of Paediatric Cancers in Hong Kong: An Interim Report
Li, C. K., Chan, G., Chik, K., Ha, S., Lau, Y., Lee, A., Lee, C., Ling, S., Luk, C. W., Shing, M., et al. (2001) · Cited by 1
Reduced Methotrexate Clearance and Renal Impairment in a Boy With Osteosarcoma and Earlier Undetected Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Alberer, M., Hoefele, J., Bergmann, C., Hartrampf, S., Hilberath, J., Pawlita, I., Albert, M. H., Benz, M. R., Weber, L. T., & Schmid, I. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181e92af4 · Cited by 1
Determinants of tumor necrosis and its impact on outcome in patients with Localized osteosarcoma uniformly treated with a response adapted regimen without high dose Methotrexate– A retrospective institutional analysis
Roy, P. G., Ganguly, S., Sasi, A., Kumar, V., Barwad, A. W., Mridha, A. R., Khan, S. A., Kumar, V. S., Kapoor, L., Pushpam, D., et al. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100651 · Cited by 1
Clinical trials of systemic therapy in osteosarcoma and Ewing’s sarcoma: past, present and future
Rowe, R. G., & Chugh, R. K. (2011) · Clinical Investigation · doi:10.4155/cli.11.128 · Cited by 1
Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility
Abe, S., Tokizaki, T., Miki, Y., Tateishi, A., Ogawa, K., Nakano, H., & Matsushita, T. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0957-0 · Cited by 1
Surgical Treatment of Tumors and Tumorlike Lesions of Bone
Walczak, B. E., Rose, P. S., Post, J. M., & Sim, F. H. (2015) · Springer eBooks · doi:10.1007/978-1-4471-6578-1_6
Letter regarding Zhang et al. entitled “Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma”
Zhu, K., Wang, W., Wu, R., & Chen, D. (2015) · Tumor Biology · doi:10.1007/s13277-015-3910-4
Spinal Infections: Evidence-Based Neuroimaging
Roudsari, B. S., & Jarvik, J. G. (2013) · Springer eBooks · doi:10.1007/978-1-4614-3320-0_33
Current Concept and New Strategy in Osteosarcoma Management
Kim, J. D. (2006) · Journal of the Korean Medical Association · doi:10.5124/jkma.2006.49.12.1119
VARIABILITY IN DOSE INTENSITY OF HIGH-DOSE METHOTREXATE FOR NONMETASTATIC OSTEOSARCOMA
Leavey, P. J., Mantadakis, E., & Maale, G. E. (2002) · Pediatric Hematology and Oncology · doi:10.1080/08880010290097305
Recurrent Bone Tumors
Lagmay, J., & Yeager, N. D. (2015) · Pediatric oncology · doi:10.1007/978-3-319-18099-1_14
Prognostic Factors and Outcome in Childhood and Adolescent Osteosarcoma: Single Institution Experience
Lee, M. J., Choe, H. Y., Jang, H. I., Jung, S. T., Choi, Y. D., Heo, S. H., Baek, H. J., & Kook, H. (2014) · Imsang soa hyeoraek jong-yang/Imsang soa hyeol'aeg jong'yang/Clinical pediatric hematology-oncology · doi:10.15264/cpho.2014.21.2.104
Current use of methotrexate in the treatment of malignancies in adults
O’Leary, J., Losev, A., & Muggia, F. M. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8452-5_3
The Role of Chemotherapy in the Treatment of Bone and Soft-tissue Sarcomas
Priebat, D. A., & Malawer, M. M. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-48407-2_3
Osteosarkom nedeniyle tedavi edilen hastalarda sakal›m analizi ve prognostik faktörlerin etkileri Survival analysis and the effects of prognostic factors in patients treated for osteosarcoma
Özger, H., Eralp, L., Atalar, A. C., Toker, B., Kebud, R., & Ba, S. (2007)
Chapter 28 - Tumor Biology and Tumor Markers
Goedegebuure, P. S., Liyanage, U. K., & Eberlein, T. J. (2004)
PET and PET/CT in Sarcoma
O'Doherty, M. J., & Smith, M. (2006) · Springer eBooks · doi:10.1007/1-84628-187-3_17
Manejo ortopédico de un osteosarcoma diafisario femoral mediante resección más injerto óseo de donador no relacionado más fijación con clavo centromedular bloqueado. Reporte de un caso
Lomas, J. D. A., & Gómez, J. C. (2008) · Revista Mexicana de Ortopedia Pediátrica
Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 1.
Humphries, P. D., & Zerizer, I. (2009) · Europe PMC (PubMed Central) · doi:10.1102/1470-7330.2009.0012
Neoadjuvant Chemotherapy: Osaka University Osteosarcoma (OOS) Regimen
Kakunaga, S., Ueda, T., Naka, N., Kuratsu, S., Araki, N., Aoki, Y., & Yoshikawa, H. (2016) · Springer eBooks · doi:10.1007/978-4-431-55696-1_8
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Musculoskeletal System: Basic Principles and Clinical Applications in Bone Sarcomas and Rheumatoid Arthritis
Wáng, Y. X. J. (2008) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812794093_0042
Non-surgical Treatment of Pediatric Bone Sarcomas
Sierrasesúmaga, L., Martín, I. R., & Garraus, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-24220-0_2
Pulmonary Manifestations of Hematologic and Oncologic Diseases
Ribeiro, R. C., Galindo, C. R., & Chantada, G. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3031-7.00007-3
History of Surgery for Limb Bone Tumors
Forriol, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-24220-0_1
Treatment of Chemosensitive-Sarcoma Patients with Metastases at Diagnosis: Possible Prognostic Value of Peripheral Blood Stem Cell Transplantation.
Tanaka, K., Katayama, A., Sakamoto, A., Matsuda, S., Iwamoto, Y., Chuman, H., & Urano, N. (2002) · Orthopedics & Traumatology · doi:10.5035/nishiseisai.51.860
Knochen- und Weichteilsarkome des Kindes-, Jugend- und jungen Erwachsenenalters
Dirksen, U., Bielack, S., Kościelniak, E., & Klingebiel, T. (2016) · Der Onkologe · doi:10.1007/s00761-016-0133-2
Chemotherapy and Other Systemic Approaches to Adult Sarcomas
Priebat, D. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-43121-5_12
What Is the Best Treatment of Malignant Bone Tumors in Children?
Gupta, A. A., & Hopyan, S. (2009) · Elsevier eBooks · doi:10.1016/b978-141604444-4.50041-2
Pediatric Solid Tumors
Dome, J. S., Galindo, C. R., Spunt, S. L., & Santana, V. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00095-3
FDG PET in the Diagnosis and Management of Pediatric and Adolescent Sarcomas
Smitherman, A. B., Gold, S., & Davis, I. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-60429-5_9
High-Dose Methotrexate (HD-MTX) Used as an Adjunct with Other Chemotherapeutics for the Treatment of Osteosarcoma
LiuYefeng, Y., Lin, X., & Ye, S. J. W. (2015)
FDG PET/CT in bone sarcomas
Camacho, M., Carvalho, M., Munhoz, R. R., Etchebehere, M., & Etchebehere, E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00062-4
Bone Sarcomas
Isakoff, M. S., Harris, M. J., Gebhardt, M. C., & Grier, H. E. (2007) · Springer eBooks · doi:10.1007/978-3-540-68152-6_12
Bone Tumors
Gorlick, R. G., Perisoglou, M., & Whelan, J. S. (2010) · Pediatric Hematology and Oncology · doi:10.1002/9781444315134.ch15
Self-citation
Osteosarcoma
Matthay, K. K. (2013) · doi:10.1002/9781118625309.ch2
Data from Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma
Kobayashi, E., Masuda, M., Nakayama, R. T., Ichikawa, H., Satow, R., Shitashige, M., Honda, K., Yamaguchi, U., Shoji, A., Tochigi, N., et al. (2023) · doi:10.1158/1535-7163.c.6531447
Data from Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma
Kobayashi, E., Masuda, M., Nakayama, R. T., Ichikawa, H., Satow, R., Shitashige, M., Honda, K., Yamaguchi, U., Shoji, A., Tochigi, N., et al. (2023) · doi:10.1158/1535-7163.c.6531447.v1
Impact of Postoperative Radiotherapy on Survival in Primary Osteosarcoma: A Population-Based StudyPreprint
Gao, H., Dang, Y.-Z., Liu, X., Chen, J., Zhao, H., Li, J., & Zhang, K. (2024) · Research Square · doi:10.21203/rs.3.rs-4433658/v1
Imaging Techniques: Magnetic Resonance Imaging (MRI)
Sun, S., & Hwang, S. (2025) · Medical radiology · doi:10.1007/174_2025_651

Authors: Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Meyers, P A
Gorlick, R
Heller, G
Lane, J
Healey, J H
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1998-07
Volume: 16
Issue: 7
Pages: 2452-2458
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1998.16.7.2452
OpenAlex: W1946181835
Cited by: 294
References: 18
Citations by year: 2025: 1 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 9 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 22 · 2013: 16 · 2012: 8
FWCI: 7.03
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Memorial Sloan-Kettering Cancer Center
National Cancer Institute (CA-09512, T32CA009512)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: osteosarcoma, neoadjuvant chemotherapy, chemotherapy intensification, cisplatin, doxorubicin, high-dose methotrexate, bleomycin, cyclophosphamide, actinomycin D, histological response, tumor necrosis, event-free survival
MeSH terms: Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Bone Neoplasms, Child, Child, Preschool, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Female, Humans, Male, Methotrexate, Necrosis, Osteosarcoma, Time Factors, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks